AI-Enabled Multimodal Biomarker Discovery for Precision Medicine
KTP Project with Chronomics Limited, London
- Funding Amount: £288,858
- Funder: Innovate UK (formerly Technology Strategy Board)
- Role: Support Academic
- Academic Team: Dr Sebastian Halder (PI), Dr Ana Matran-Fernandez (Co-I), Dr Michael Barros.
- KTP Associate: TBH
- Industry Lead: Dr Daniel Martin-Herranz
- Year: 2025 - 2028
Recent advances in Artificial Intelligence (AI) and Machine Learning (ML) are transforming precision medicine by enabling more accurate biomarker discovery. Biomarkers play a vital role in diagnosing disease, predicting risk, monitoring treatment, and supporting clinical trials. Chronomics (trading as Hurdle) aims to strengthen its innovation capacity by embedding advanced AI/ML techniques into its biomarker pipeline. This project will develop an AI-enabled biomarker discovery engine, integrating multimodal datasets such as time-series, imaging, and electronic health records. The outcome will be new, commercially viable risk prediction tools, advancing public health while positioning Hurdle to expand in the global precision medicine market.